Pulmonx’s (LUNG) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Pulmonx (NASDAQ:LUNG) in a research report released on Friday morning,Benzinga reports. The firm currently has a $14.00 target price on the stock.

Other research analysts have also recently issued reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Lake Street Capital lowered their price target on shares of Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, October 28th. Finally, Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Five investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $6.81.

Pulmonx Trading Up 6.0%

NASDAQ LUNG opened at $1.51 on Friday. The business’s fifty day moving average is $1.92 and its 200-day moving average is $1.79. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.86 and a quick ratio of 4.15. The stock has a market capitalization of $62.08 million, a price-to-earnings ratio of -1.07 and a beta of 0.07. Pulmonx has a one year low of $1.31 and a one year high of $9.35.

Institutional Trading of Pulmonx

Institutional investors and hedge funds have recently modified their holdings of the business. R Squared Ltd bought a new stake in shares of Pulmonx during the 2nd quarter valued at about $41,000. Fjarde AP Fonden Fourth Swedish National Pension Fund purchased a new stake in Pulmonx in the second quarter valued at approximately $197,000. Bank of Montreal Can bought a new stake in Pulmonx during the second quarter valued at approximately $53,000. Corton Capital Inc. purchased a new position in Pulmonx in the 2nd quarter worth approximately $32,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Pulmonx in the 2nd quarter worth $84,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.